drugset / Trial / NCT00996216
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy.
Timeline
- Start
- 2009-09
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | — | — |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Background | Ribavirin | Small molecule | — | — |
| Background | alfa-2b | Unknown | — | — |